Gold prices slip lower; consolidating after recent gains
LOS ANGELES - Niagen Bioscience, Inc. (NASDAQ: NAGE), a $469 million market cap company formerly known as ChromaDex Corp., has stated its operations and product supply chain will remain stable in light of recent global tariffs. According to InvestingPro data, the stock has shown significant momentum with an 81% gain over the past six months, despite recent volatility. The company, a leader in NAD+ science and healthy aging research, has its Niagen® ingredient and related products manufactured entirely within the United States, which it believes will minimize the impact of international trade volatility.
Niagen Bioscience’s CEO, Rob Fried, emphasized the company’s strategic decision to establish a U.S.-based supply chain for its patented nicotinamide riboside (NR) ingredient, Niagen. This foresight has positioned the company to continue its operations without disruptions due to global price fluctuations. InvestingPro data reveals the company’s strong financial position, with a healthy current ratio of 3.57 and minimal debt-to-equity ratio of 0.06, suggesting robust operational stability. Fried expressed confidence in the company’s ability to maintain product delivery and price stability for customers and shareholders.
The company’s revenue from international sales in 2024 was approximately 24%, with over 12% coming from A.S. Watson in Hong Kong, a market not affected by tariffs. Financial data from InvestingPro shows impressive revenue growth of 19.2% in the last twelve months, with total revenue reaching $99.6 million and a strong gross profit margin of 61.8%. The exemption of most vitamins, including NR, from the recently enacted tariffs has allowed Niagen Bioscience to sustain its international operations without interruption.
Niagen Bioscience’s product portfolio centers on Niagen®, the most efficient NAD+ booster available, which powers Tru Niagen®, a leading oral supplement in the U.S., and Niagen Plus™, a line of pharmaceutical-grade intravenous and injectable products. The company’s robust patent portfolio protects NR and other NAD+ precursors, ensuring a competitive edge in the market.
Despite the forward-looking statements regarding the potential impact of tariffs on the company’s business operations and financial performance, Niagen Bioscience assures no anticipated disruptions to its ability to deliver products or maintain costs and pricing. For detailed analysis of NAGE’s financial health, valuation metrics, and 13 additional exclusive ProTips, investors can access the comprehensive Pro Research Report available on InvestingPro. This announcement is based on a press release statement from Niagen Bioscience.
In other recent news, Niagen Bioscience, formerly known as ChromaDex, reported impressive financial results for the fourth quarter of 2024. The company exceeded earnings expectations with an earnings per share (EPS) of $0.09, significantly above the forecasted $0.02. Revenue for the quarter reached $29.1 million, surpassing the anticipated $26.78 million, marking a 37% increase year-over-year. H.C. Wainwright responded by raising the company’s stock price target to $11.00 and maintaining a Buy rating, citing the company’s strong performance and growth prospects. Additionally, Niagen Bioscience has expanded its intellectual property portfolio with a new U.S. patent for various forms of nicotinamide riboside (NR) salts, which are critical for cellular health. The patent is expected to provide exclusive rights until 2034, strengthening the company’s position in the market for NAD+ precursors. The company also announced a corporate rebranding, transitioning from ChromaDex to Niagen Bioscience, which aligns with its focus on its flagship ingredient, Niagen. This rebranding is seen as a strategic move to better represent its mission and product offerings in the healthy aging sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.